OBJECTIVE: To describe growth in infants <32 weeks GA. To assess the relationship between growth and perinatal factors (like intrauterine growth retardation and the postnatal use of dexamethasone) and neurodevelopmental outcome. DESIGN: Regional, prospective study in two health regions in the Netherlands. Part of the Leiden Follow-Up Project on Prematurity (LFUPP). PATIENTS: 196 live born infants with GA <32 weeks. METHODS: At two years corrected age length, weight and head circumference of 160 of 196 surviving infants (82%) were evaluated. Standard Deviation Scores were calculated and means were compared to Dutch growth references. Mean SDS for length was corrected for the mean SDS for target height. Birth weight (BW)-SDS for gestational age (GA) was calculated according to Swedish references. RESULTS: Length, weight and weight-for-length were equally impaired in both sexes at two years in premature infants compared to Dutch growth charts. Catch-up in length and weight occurred mostly in the first year of life. Intrauterine growth retardation was associated with impairment of all growth parameters. The use of postnatal dexamethasone was associated with shorter length, lower weight, lower weight for length and smaller head circumference; this effect remained after correction for GA, BW and BW-SDS. Growth retardation (length and weight) was associated with an abnormal neurologic examination; smaller head circumference also with mental and psychomotor delay. CONCLUSION: Growth at two years corrected age in children born <32 weeks is impaired. Postnatal dexamethasone is associated with impairment of all growth parameters including head circumference, which may be a significant contributing factor for abnormal neurodevelopmental outcome.
OBJECTIVE: To describe growth in infants <32 weeks GA. To assess the relationship between growth and perinatal factors (like intrauterine growth retardation and the postnatal use of dexamethasone) and neurodevelopmental outcome. DESIGN: Regional, prospective study in two health regions in the Netherlands. Part of the Leiden Follow-Up Project on Prematurity (LFUPP). PATIENTS: 196 live born infants with GA <32 weeks. METHODS: At two years corrected age length, weight and head circumference of 160 of 196 surviving infants (82%) were evaluated. Standard Deviation Scores were calculated and means were compared to Dutch growth references. Mean SDS for length was corrected for the mean SDS for target height. Birth weight (BW)-SDS for gestational age (GA) was calculated according to Swedish references. RESULTS: Length, weight and weight-for-length were equally impaired in both sexes at two years in premature infants compared to Dutch growth charts. Catch-up in length and weight occurred mostly in the first year of life. Intrauterine growth retardation was associated with impairment of all growth parameters. The use of postnatal dexamethasone was associated with shorter length, lower weight, lower weight for length and smaller head circumference; this effect remained after correction for GA, BW and BW-SDS. Growth retardation (length and weight) was associated with an abnormal neurologic examination; smaller head circumference also with mental and psychomotor delay. CONCLUSION: Growth at two years corrected age in children born <32 weeks is impaired. Postnatal dexamethasone is associated with impairment of all growth parameters including head circumference, which may be a significant contributing factor for abnormal neurodevelopmental outcome.
Authors: William F Carroll; Jorge Fabres; Tim R Nagy; Marcela Frazier; Claire Roane; Frank Pohlandt; Waldemar A Carlo; Ulrich H Thome Journal: J Pediatr Gastroenterol Nutr Date: 2011-09 Impact factor: 2.839
Authors: Danilo R de Moura; Jaderson C Costa; Iná S Santos; Aluísio J D Barros; Alicia Matijasevich; Ricardo Halpern; Samuel Dumith; Simone Karam; Fernando C Barros Journal: Paediatr Perinat Epidemiol Date: 2010-05 Impact factor: 3.980
Authors: Inês Sá-Pereira; Jay Roodselaar; Yvonne Couch; Marcia Consentino Kronka Sosthenes; Matthew C Evans; Daniel C Anthony; Helen B Stolp Journal: Brain Behav Immun Date: 2018-01-31 Impact factor: 7.217
Authors: Deodata Tijsseling; Maike Ter Wolbeek; Jan B Derks; Willem B de Vries; Cobi J Heijnen; Frank van Bel; Eduard J H Mulder Journal: PLoS One Date: 2018-02-12 Impact factor: 3.240
Authors: Sander Brons; Machteld E van Beusichem; Ewald M Bronkhorst; Jos M Draaisma; Stefaan J Bergé; Jan G Schols; Anne Marie Kuijpers-Jagtman Journal: PLoS One Date: 2014-02-27 Impact factor: 3.240
Authors: Man Zhang; Marufu Martin Gazimbi; Zhong Chen; Bin Zhang; Yanru Chen; Yizhen Yu; Jie Tang Journal: BMJ Open Date: 2020-01-02 Impact factor: 2.692